CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

February 23, 2029

Study Completion Date

February 23, 2044

Conditions
Leukemia, Myeloid, Acute
Interventions
BIOLOGICAL

CD33KO-HSPC; CART33

"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER